Subcutaneous infusion of high-dose benzathine penicillin G is safe, tolerable, and suitable for less-frequent dosing for rheumatic heart disease secondary prophylaxis: a phase 1 open-label population pharmacokinetic study.

"The authors declare no conflict of interest."

"This research was funded by Cure Kids NZ (Grant number 7012). The funders had no role in the study design, data collection and interpretation, or the decision to submit the work for publication. J.K. is supported by a Strep A PhD Scholarship and a Scholarship for International Research Fees at the University of Western Australia (UWA). T.K.H. is supported by a Post Graduate Research Scholarship at the University of Western Australia, partly funded by the Athelstan Saw Bequest Fund. S.E. is supported by a Research Program Training scholarship at UWA and a Wesfarmers Centre of Vaccines and Infectious Diseases Top Up scholarship. L.M. and J.C. are supported by NHMRC Investigator Awards (GNT1197177 and GNT 1173874, respectively)."

"We conducted a phase 1 open-label study using three cohorts with increasing doses of BPG, with the primary objective of assessing the safety and tolerability of SCIP. The secondary objectives were to characterize the PK, including the time above the current accepted pharmacological surrogate for protection against S. pyogenes and any potential effect of body composition on absorption profiles. The protocol was approved by the Bellberry Human Research Ethics Committee (2020-12-1348) and prospectively registered (Australian and New Zealand Clinical Trial Registry; ACTRN12621000135819). All participants provided written informed consent."